Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional)
- Not stated
- Not stated
- Jun 9, 2026
Official announcement on Grants.gov · opens the funder's page. Always confirm dates there.
Or read the full text and all 7 standing review criteria here, free with an account. Create free account
Summary
The National Institute on Drug Abuse (NIDA) Avant-Garde and Avenir Awards Program for HIV Research supports exceptionally creative scientists, who propose high-impact studies that open new areas of HIV research in the context of substance use and Substance Use Disorders (SUD) and/or lead to new avenues for HIV prevention, treatment and…
The full announcement, free with an account
- The full announcement text, not just the first two sentences
- All 7 standing review criteria National Institutes of Health applies to this kind of proposal (its standard framework, not criteria written for this announcement)
On Plus, $39 a month
- The eligibility check against your profile: career stage, institution type, and the windows that close before the deadline does
- Funded precedents: what similar NIH projects received, from the award records in NIH RePORTER
- A Reviewer Scorecard of your draft against these criteria
More from National Institutes of Health
NIDCR Drug, Biologic, Device and/or Procedure Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed)
$500k